GSK PLC closed 11.51% short of its 52-week high of £16.79, which the company achieved on September 9th.

GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for ...

A “heavy workload” and “limited resources” have left the agency unable to meet a June 17 deadline to approve a therapy ...

GSK plc (LSE/NYSE: GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support individuals impacted with lupus, particularly systemic lupus erythematosus (SLE) and ...

Sage Therapeutics Inc. has found itself a buyer that bested the unsolicited acquisition offer a few months ago from fellow ...

"NICE approves GSK’s belantamab mafodotin for blood cancer" was originally created and published by Pharmaceutical Technology ...

Recent collaborations highlight a growing interest in building a multiomics-based understanding of health and disease.

GSK PLC GSK shares dropped 2.45% to £15.12 Friday, on what proved to be an all-around poor trading session for the stock ...

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...

The partnership includes support for the design of the Phase III trial and assistance in securing external funding.

Patients with eosinophilic granulomatosis with polyangiitis experienced significant improvements in a variety of outcomes ...

Arexvy was the first RSV vaccine approved in the European Economic Area for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older, and for those aged 50 to 59 ...